Navigation Links
Chemical compounds in trees can fight deadly staph infections in humans
Date:2/22/2011

s Center, identified, isolated and tested 17 bioactive compounds and has plans to analyze more compounds. Scientists found that a relatively small concentration of a chemical compound found in the Eastern Red Cedar 5 micrograms per milliliter was effective against MRSA. The team tested the compound's effectiveness against many versions of MRSA in a test tube with promising initial results.

"We found this chemical from the cedar needles, an abundant and renewable resource that can be collected annually," co-researcher Brian Thompson said. "Because the compound is in the needles, we don't have to cut down the trees."

In addition to its potential use in fighting MRSA, researchers found that some chemical compounds in the tree are able to fight and kill skin cancer cells present in mice. It may also be effective as a topical acne treatment. Stewart said the compounds are years away from commercial use, as they must go through clinical trials. The team's research was presented recently at the International Conference on Gram-Positive Pathogens.


'/>"/>

Contact: Christian Basi
BasiC@missouri.edu
573-882-4430
University of Missouri-Columbia
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Chemical engineer earns National Science Foundation CAREER award for work with graphene quantum dots
2. LSU biologist, chemical engineer partner with industry to develop best soft lure available
3. Ben-Gurion U. and PTT Chemical sign R&D agreement to commercialize green algae strain
4. Quality standards for biological, chemical drugs and public health are focus of India meeting
5. With chemical modification, stable RNA nanoparticles go 3-D
6. Manchester leads green chemical training push
7. UCSF study identifies chemicals in pregnant women
8. Press registration opens for American Chemical Society National Meeting, March 27-31, 2011
9. Long-lasting chemicals threaten the environment and human health
10. Boosting supply of key brain chemical reduces fatigue in mice
11. Rensselaer Polytechnic Institute professor Georges Belfort wins biochemical engineering award
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Chemical compounds in trees can fight deadly staph infections in humans
(Date:4/9/2015)... SAN JOSE, Calif. , April 9, 2015 /PRNewswire/ ... of human interface solutions, announced today that it will ... 2015 on Thursday, April 23, 2015, after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
(Date:4/2/2015)... , April 2, 2015 ... tests DERMALOG by far outperforms the strongest competitors, ... maintaining high accuracy, the system is capable of ... the speed proves up to be ten times ... than its runner-up performance.      (Photo: ...
(Date:4/2/2015)... , April 2, 2015 Fingerprint ... fingerprint sensor FPC1025 from the distributor World Peace Industrial ... during Q2 2015 although the major part of the ... will be used by smartphone manufacturers in ... is included in the communicated revenue guidance of + ...
Breaking Biology News(10 mins):Synaptics to Report Third Quarter Results on April 23 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
... and two collaborators have received a $3.4 million research ... of prostate cancer using MRI, or magnetic resonance imaging. ... two years from the American Recovery and Reinvestment Act ... of Health under an initiative to promote industry and ...
... A new internet-based tool for designing agricultural terraces ... optimize design by allowing rapid development of alternative layouts. ... Resource: Engineering & Technology for a Sustainable World , ... Engineering at the University of Missouri, introduces a web-based, ...
... species are not just discovered in exotic localeseven places ... plants and animals. Academy scientists recently named a new ... fishes distantly related to sharks, from the coast of ... the Eastern Pacific black ghostshark ( Hydrolagus melanophasma ), ...
Cached Biology News:Rutgers to collaborate in $3.4 million effort to improve prostate cancer identification using MRI 2Web-based innovation improves, eases agricultural terrace design 2New species of ghostshark from California and Baja California 2
(Date:4/16/2015)... Switzerland , April 16, 2015 /PRNewswire/ ... Debiopharm Group ™ , a Swiss-based global biopharmaceutical ... medical needs as well as companion diagnostics, ... investigational compounds Debio 1143 (SMAC mimetic) and Debio 1347/CH5183284 ... the 2015 Annual meeting of the American Association for Cancer Research ...
(Date:4/16/2015)... 2015 Fairleigh Dickinson University ( ... to become the Executive Director of the Rothman ... the kick-off of the Initiative for Patient Centered ... Gulfo, under the Rothman Institute of Innovation and ... in collaboration with FDU’s School of Pharmacy’s Center ...
(Date:4/16/2015)... Seattle, Washington (PRWEB) April 16, 2015 ... for Applied Cancer Science and Resolution Bioscience, Inc. ... agreement to co-develop a novel, blood-based, clinic ready, ... lung cancer (NSCLC). The collaboration is the first ... ALK, RET, and ROS1 fusions in blinded plasma ...
(Date:4/16/2015)... 2015 CCI Global Channel Management, the ... planning management software for major tech and telecom vendors, ... survey of channel vendor programs in software, hardware, and ... How the top IT vendors in each segment ... coming year. , Assessment of the state ...
Breaking Biology Technology:Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 3Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 2Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 3CCI’s Channel Program Study Reveals 40% of IT Vendor Channel Staff Lack Adequate Access to Program and Partner Data 2CCI’s Channel Program Study Reveals 40% of IT Vendor Channel Staff Lack Adequate Access to Program and Partner Data 3
... to the Advanced Performance of the A1 Series of ... , MELVILLE, N.Y., Dec. 15 Offering ... Nikon Instruments, Inc.,s ( www.nikoninstruments.com ) A1 series of ... software brings biological imaging to life. The software, ...
... Scientific,Corporation (NYSE: BSX ) today announced that ... Express(R) SD Renal Monorail(R),Premounted Stent System for use as ... lesions of the renal arteries. The,Express SD System ... renal arteries in the United States. It is ...
... 15 Cylene Pharmaceuticals today announced,the initiation of ... in,patients with carcinoid/neuroendocrine tumors (C/NET), which are malignant,cancers ... "Quarfloxin (CX-3543) is a ... in the abnormal nucleoli of cancer cells, thereby,selectively ...
Cached Biology Technology:Nikon Instruments A1 Confocal Laser Microscope Series With NIS-Elements C Software Delivers Fully Integrated Comprehensive Confocal Imaging Capabilities 2Nikon Instruments A1 Confocal Laser Microscope Series With NIS-Elements C Software Delivers Fully Integrated Comprehensive Confocal Imaging Capabilities 3FDA Approves Boston Scientific's Express(R) SD Renal Stent System 2FDA Approves Boston Scientific's Express(R) SD Renal Stent System 3FDA Approves Boston Scientific's Express(R) SD Renal Stent System 4Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors 2Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors 3